Objective. To increase the efficiency of chemoradiotherapy with dynamic accelerated hyperfractionation with concomitant boost for locally advanced cancer of the oral cavity, tongue, pharynx.
Materials and methods. A randomized clinical trial included 280 men with squamous cell carcinoma of the oral cavity, tongue, or pharynx III and IVA, B stages. After assessing compliance with the inclusion criteria, all patients were randomized to the main and control groups. In the main group, chemoradiotherapy was performed with dynamic accelerated hyperfractionation with concomitant boost. In the control group, the conventional chemoradiotherapy was used. A comparative analysis of the patients’ overall and cancer specific survivals was carried out.
Results. Statistically significant differences (p<0.001) between the groups with the 5-year overall and cancer specific survivals in the main group (46.2±5% and 59±5% respectively) and in the control group (20.9±4% and 23.5±4% respectively) were sound.
Conclusion. The best results in managing patients for locally advanced cancer of the oropharyngeal zone were obtained when radiotherapy with dynamic accelerated hyperfractionation with concomitant boost was applied.Ключевые слова:
Автор(ы): L. B. Parkhomenko, N. I. Krutilina, O. V. Krasko